In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...
Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...
ROME — The Project Fibonacci Foundation has announced the guest speakers for the upcoming 7th annual STEAM Leadership Conference, as well as a 3-year partnership with NYSTEC (the New York State ...
Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...
Abstract: We observe that the computational inefficiency of branched recursive functions was not appropriately covered in almost all textbooks for computer science courses in the first three years of ...
For centuries, the phrase "beauty is in the eye of the beholder" has dominated discussions of aesthetics. This adage suggests that beauty is entirely subjective—what one person finds attractive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results